Together, our findings uncover an ARIH2-NUPR1 regulatory axis that drives BLCA progression by suppressing ferroptosis and favouring an immunosuppressive microenvironment, highlighting this pathway as a potential therapeutic target in BLCA. This evidence concerns the gene NUPR1 and bladder transitional cell carcinoma.